Global NewsNewsStrategy

Gamma Biosciences acquires controlling stake in Mirus Bio

To expand reach in gene therapy and next-generation vaccines

Gamma Biosciences has agreed to make a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Madison, Wisconsin. Current Mirus shareholders will retain a substantial equity ownership stake in the company.

The transaction will support Mirus’ plans to expand good manufacturing practice (GMP) production and commercialization of its flagship product TransIT VirusGEN for large scale manufacturing of AAV and LV-based viral vectors for gene therapy, as well as further development and commercialisation of the platform for in vivo delivery applications. 

Originally developed for therapeutic delivery of RNA, Mirus LPNCs have been adapted for a wide range of gene delivery applications. Demand for efficient and scalable gene delivery technologies continues to increase as larger volumes of viral vector are required to support the growing number of gene therapies in development. TransIT VirusGen and Mirus’ portfolio of additional products and services enable customers at both research and clinical scales to achieve cost-effective, industry-leading functional titers.

Mirus will leverage Gamma Bio’s strategic and commercial resources and will work closely with its other operating companies, including Univercells Technologies, Astrea Bioseparations, Nanopareil and BioMagnetic Solutions, to deliver an increasingly comprehensive range of solutions for the advanced therapy industry.

“Highly efficient, GMP compliant nucleic acid delivery into a wide variety of cell types will continue to be a critical path item for advanced therapies, from viral vectors such as AAV for gene therapy to engineered cellular therapies to novel mRNA based vaccines,” said Matt Gunnison, President, Gamma Biosciences. “Mirus brings decades of experience in transfection and cell engineering and a portfolio of best-in-class transfection products for in vitro and in vivo delivery, adding a new foundational platform that complements Gamma’s existing offering in advanced therapy manufacturing.”

“Delivery of biomolecules into cells is a mainstay of Mirus’ impact on biology research. Doing this efficiently, across a broad range of cells, while maximising cell viability and recovery is what Mirus Bio has excelled at for more than 25 years,” said Jim Hagstrom, President and Co-founder of Mirus Bio. 

Rothschild & Co served as exclusive financial advisor and Quarles and Brady served as legal advisor to Mirus. Sidley Austin served as legal advisor to Gamma.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Leave a Reply

Back to top button